Glucotrack Innovates Diabetes Management with Implantable Glucose Monitor

Glucotrack Inc. (NASDAQ: GCTK) is pioneering a new approach to diabetes management with its fully implantable continuous blood glucose monitoring (CBGM) system. By forming a Patient Advisory Board (PAB), the company has directly incorporated feedback from individuals living with type 1 diabetes, highlighting widespread distrust in current glucose monitoring solutions due to inaccuracies, false alarms, and allergic reactions.

The CBGM system offers long-term functionality, requiring minimal maintenance and designed to last up to 3 years. Unlike traditional systems, it eliminates the need for adhesives and provides direct blood glucose measurements, improving trust in the accuracy of real-time data. A first-in-human feasibility study in Brazil showed promising results, with a 99% data capture rate and an average MARD of 6.7%, outperforming many commercially available CGM systems.

With ethical approval for a year-long clinical study in Australia, Glucotrack is set to further evaluate the CBGM's performance and safety. The study, led by prominent diabetes researchers, aims to confirm the system's potential to improve glycemic control and offer patients more accurate real-time glucose values. Glucotrack's participation in the 2025 American Diabetes Association Scientific Sessions will showcase its innovative technology to healthcare professionals, marking a significant step forward in diabetes care.

This development is crucial for the millions of individuals managing diabetes worldwide, offering a more reliable and less intrusive monitoring option. The implications extend beyond patient convenience, potentially reducing the emotional and clinical burdens associated with current diabetes management tools and setting a new benchmark for the industry.